Home
/
LIGAND PHARMACEUTICALS INC
/
Financials
/
Quarterly
LIGAND PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that LIGAND PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$56.16M
May 9, 2018
Q3
2017
Sep 30, 2017
$33.38M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$28.00M
Aug 9, 2017
Q1
2018
Mar 31, 2017
$29.27M
May 9, 2018
Q3
2017
Sep 30, 2016
$21.62M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$19.52M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$29.65M
May 9, 2017
Q3
2016
Sep 30, 2015
$17.70M
Nov 14, 2016
Q2
2016
Jun 30, 2015
$18.42M
Nov 14, 2016
Q1
2016
Mar 31, 2015
$14.60M
Nov 14, 2016
Q3
2015
Sep 30, 2014
$14.97M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$10.61M
Aug 5, 2015
Q1
2015
Mar 31, 2014
$15.96M
May 11, 2015
Q3
2014
Sep 30, 2013
$13.01M
Oct 31, 2014
Q2
2014
Jun 30, 2013
$9.58M
Aug 5, 2014
Q1
2014
Mar 31, 2013
$11.65M
May 7, 2014
Q3
2013
Sep 30, 2012
$6.38M
Nov 8, 2013
Q2
2013
Jun 30, 2012
$5.74M
Aug 1, 2013
Q1
2013
Mar 31, 2012
$5.64M
May 8, 2013
Q3
2012
Sep 30, 2011
$5.74M
Nov 14, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$115.46M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$47.63M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$45.33M
May 9, 2025
Q3
2025
Sep 30, 2024
$51.81M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$41.53M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$30.98M
May 9, 2025
Q3
2024
Sep 30, 2023
$32.87M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$26.37M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$43.98M
May 8, 2024
Q3
2023
Sep 30, 2022
$59.22M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$50.13M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$36.52M
May 8, 2023
Q3
2022
Sep 30, 2021
$64.84M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$84.68M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$55.15M
May 9, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$117.27M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$4.85M
Aug 8, 2025
Q2
2025
Mar 31, 2025
($42.45M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($42.45M)
May 9, 2025
Q3
2025
Sep 30, 2024
($7.17M)
Nov 7, 2025
Q3
2025
Jun 30, 2024
($51.91M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($51.91M)
Aug 8, 2025
Q2
2025
Mar 31, 2024
$86.14M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$86.14M
May 9, 2025
Q3
2025
Mar 31, 2024
$86.14M
Nov 7, 2025
Q3
2024
Sep 30, 2023
($10.27M)
Nov 8, 2024
Q3
2024
Jun 30, 2023
$2.29M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$2.29M
Aug 7, 2024
Q2
2024
Mar 31, 2023
$41.95M
Aug 7, 2024
Q3
2024
Mar 31, 2023
$41.95M
Nov 8, 2024
Q1
2024
Mar 31, 2023
$41.95M
May 8, 2024
Q3
2023
Sep 30, 2022
$404.0K
Nov 9, 2023
Q3
2023
Jun 30, 2022
($895.0K)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($895.0K)
Aug 9, 2023
Q2
2023
Mar 31, 2022
($15.39M)
Aug 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$54.93M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$8.44M
Aug 8, 2025
Q1
2025
Mar 31, 2025
($36.22M)
May 9, 2025
Q3
2025
Sep 30, 2024
$3.14M
Nov 7, 2025
Q2
2025
Jun 30, 2024
($19.10M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
$2.99M
May 9, 2025
Q3
2024
Sep 30, 2023
$3.08M
Nov 8, 2024
Q2
2024
Jun 30, 2023
($1.98M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
$14.21M
May 8, 2024
Q3
2023
Sep 30, 2022
$12.34M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$8.66M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$2.13M
May 8, 2023
Q3
2022
Sep 30, 2021
$15.71M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$45.74M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$4.72M
May 9, 2022
Q3
2021
Sep 30, 2020
$3.75M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$7.10M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$3.79M
May 6, 2021
Q3
2020
Sep 30, 2019
($5.16M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($4.13M)
Aug 7, 2020